BALTIMORE, April 8 /PRNewswire-FirstCall/ -- Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established a UK subsidiary, Champions Biotechnology UK Ltd. (CBUK), to expand its personalized oncology business. Guy Malchi has been appointed General Manager of the UK subsidiary, which will also have a branch in Israel.
"We have been experiencing an increase in activity in all of our business, particularly in our personalized oncology service. Significantly, much of the increased activity in our personalized oncology business is from leading oncologists in Europe as they recognize the enhancement to their practice that is available by utilizing Champions' services. Champions Biotechnology UK Ltd. will enable our services to be accessible to many more physicians in Europe and beyond. The growing trend of medical tourism in Israel has prompted us to establish a branch in Israel to offer our services there as well," said Doug Burkett, PhD, President of Champions Biotechnology, Inc.
Dr. Burkett continued, "I am delighted to welcome Guy Malchi on board as he transitions from consultant to take on the leadership role for CBUK. He will also lead our corporate development efforts, which are focused on in-licensing and co-development of oncology drug candidates that have proven successful in our Biomerk Tumorgraft(TM) platform. Guy's expertise in strategy implementation and business development are a valuable benefit to Champions."
"I am thrilled to join Champions Biotechnology to help it realize its high potential," said Mr. Malchi. "I was drawn to the unique interaction between personalized medicine and drug development, and I look forward to contributing to the firm's success."
Guy Malchi, MBA brings more than twelve years
|SOURCE Champions Biotechnology, Inc.|
Copyright©2009 PR Newswire.
All rights reserved